1300 GMT - Roche's $50 billion U.S. investment signals that president Trump's pressure tactics amid tariffs prospects are proving effective, AlphaValue analysts say in a note. The Swiss pharma giant's five-year $50 billion pledge in U.S. manufacturing and R&D joins a growing trend of companies increasing investment in the country, they say. Roche shares fall 2% to 250.60 Swiss Francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 22, 2025 09:03 ET (13:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.